Our investment philosophy is based on the compelling logic that equity returns of individual companies always follow their fundamental value creation in the long-term. Hence, positive Fundamental Returns (value creation) are the single most important determinant of long-term investment success.
Abaris Biotechnology Opportunities is an offensive investment solution to generate extraordinary long-term equity returns. The fund invests in a diversified portfolio of early stage biopharma companies with blockbuster potential as well as hyper growth biotech companies that overproportionally benefit from biotechnology mega trends (“pure plays”).
The fund invests free from any benchmark and market cap orientation.
Volatility, >30% p.a.
Small-, Mid Caps
(Investment Universe: >1,000 Equities)
Long Only Equities
portfolio companies in the Abaris Biotechnology Opportunities fund currently
benefit from megatrends, such as:
* Ranges and average numbers serve as indications and shall not be
interpreted as hard investment limits
of the website of Abaris Investment Management AG ("AIM") agree to
the following terms and conditions. Without such declaration of consent, the
AIM website may not be visited.
Some of the collective investment schemes named on the AIM website have not yet been authorized by the Swiss Financial Market Supervisory Authority FINMA for distribution in or from Switzerland. Therefore, all related information is exclusively addressed to qualified investors as defined in Art. 10 para. 3 of the Swiss Federal Act on Collective Investment Schemes (CISA).
The AIM Website is not intended for persons who, by reason of their nationality, place of business, residence or other reasons, are subject to any jurisdiction that prohibits the publication of or access to the content of the AIM Website.
Information published on the AIM website does not constitute a recommendation, an offer or a solicitation to buy or sell collective investment schemes, to engage in securities transactions or to conclude any legal transaction. Furthermore, information on the AIM website may neither serve as a basis for any decision-making with regard to any economic, legal, tax or other advisory issues, nor as a basis for investment decisions or other decisions solely on the basis of this information. Consultation with a qualified professional is essential and is hereby explicitly recommended.
The entire content of the AIM website is protected by intellectual property rights. You may download or print out a hard copy of individual pages and/or sections of the AIM website, provided any copyright or other proprietary notices are not removed and remain visible on such copies. All property rights remain with AIM. The complete or partial reproduction, transmission (electronically or by other means), modification, linking or use of the AIM website for public or commercial purposes is prohibited without the prior written consent of AIM.
The information published and opinions expressed on the AIM website are provided by AIM for personal use and informational purposes only and are subject to change without notice. AIM does not guarantee the accuracy, completeness or timeliness of the information and statements on the AIM website. AIM disclaims, without limitation, all liability for any loss or damage of any kind, whether direct, indirect or consequential, which might arise from the use of the AIM website, reliance on any information published on the AIM website, or any links to third-party websites.
Past performance is not indicative of future performance. Potential investors should note that investments may involve substantial risks and the investment value may increase or decrease.